u/Tasty-AH750

I woke up to Moderna doubling its market cap, adding over 25 Billion dollars to its worth. The reason: their mRNA melanoma vaccine paired with Keytruda beat Keytruda alone in a Phase 3 trial. Recurrence and metastasis risk both dropped significantly. Market reaction was immediate and brutal in the best way, tens of billions added to Moderna's valuation even before the open.

That's what happens when a combination therapy with Keytruda actually works in a real trial. Merck's drug is approved in more than 40 cancer indications and pharma companies have spent years trying to find partners that meaningfully improve on it. When one does, the market doesn't wait around to price it in.

Alpha Tau ($DRTS) is running the same playbook, and most people haven't noticed yet.

At AHNS in July, Alpha Tau presented mature data from the Hadassah combination trial: Alpha DaRT plus pembrolizumab (Keytruda) in elderly head and neck cancer patients. A 100% objective response rate and 18.2 month median overall survival, both clearing the study's pre-specified bar for success. The lead investigator at Hadassah said he wasn't aware of any other pembrolizumab combination study that had put up numbers like that in this population.

And now Alpha Tau is in active discussions with the FDA about running a larger multi center US trial of the same combination. That's the same regulatory conversation Moderna just proved is worth having. A positive Keytruda combination signal is one of the more valuable things a company can bring to that table, because it opens the door to a much bigger addressable population than any single indication on its own.

Different tumor types, different mechanism, but the underlying thesis is identical: pair with the best selling immunotherapy on the planet, show you make it work better, and let the market figure out what that's worth.

Moderna just got that repricing in a single morning. Alpha Tau is still trading like nobody's looked at the data yet.

I want to focus on what I think is the real catalyst here. DRTS just wrapped a study combining Alpha DaRT with Keytruda in head and neck cancer patients, and it hit a 100% objective response rate (4 complete responses and 5 partial responses out of 9 evaluable patients) with median overall survival of 18.2 months. The trial met its prespecified success threshold and enrollment is already complete. Yes, nine patients is a small sample size, but in oncology, jumping from a roughly 19% historical response rate to 100%, and extending survival from 12.3 months to 18.2 months in a frail population, is a massive signal.

In the last press release, CEO Uzi Sofer directly addressed what comes next. He said the company is exploring, in his words, the idea of "a similar but larger study" done in the US, and that these talks are already happening with the FDA. That is about as clear a signal as you are going to get from a CEO without them just announcing the filing outright.

In my read that points toward a new IDE for a larger pembrolizumab combination study, and this would be the most important one this company has filed. Every prior IDE here opened a small feasibility study. This one would be building on data that already blew past the historical Keytruda monotherapy benchmark. Head and neck cancer is roughly 890,000 new cases a year worldwide, so a bigger trial approved on the back of numbers like that would move this from a small early study into a real pipeline asset with genuine commercial potential.

Now here is the part that makes the timing interesting to me. DRTS closed yesterday at 11.55, down from the low 14s just last week, even after that data came out. So you have what I think is the most significant IDE this company has ever pursued potentially coming, and the stock has cooled off instead of running up. That is the setup I want to see: strong data already banked, a much bigger trial likely on the way, and a price that gives some room before the next catalyst instead of already pricing it in.

None of this is guaranteed and small cap biotech can move fast in both directions, but if that IDE comes through, I think the gap between where the stock sits now and where it could reprice to is significant.

Curious if anyone else is seeing this too and if anyone has a sense of timing on when the FDA might respond.

Not financial advice, just my own research and opinion.

This one's a little different from the last two since it's not even on the market yet, but it's worth understanding because it's a real piece of the future pipeline.

Back in February 2026, lifeward signed a deal to acquire the technology, IP, and prototypes from an Israeli company called Skelable. total consideration is up to $500,000, with $480,000 paid in lifeward stock across milestone based installments and $20,000 in cash at closing. cheap deal for what they're getting.

Skelable is a powered exoskeleton for the upper body, meaning arms and hands, with AI built in. It's designed to assist functional movement and restore function in people with weakened or paralyzed arms and hands, mainly stroke survivors. Think of it as rewalk's cousin, but instead of helping someone walk again, this one helps someone use their arm and hand again for everyday tasks they otherwise couldn't do alone.

Market for the Skelable in the US alone, there are around 245,000 people who are newly diagnosed with stroke related upper limb impairment every year, and of the more than 7 million stroke survivors total, roughly two thirds remain disabled, which adds up to about 4.6 million people who could be candidates for this kind of device. That's a massive pool of potential patients that lifeward currently has zero presence in.

Skelable fits so well with what LFWDalready do. The same doctors who prescribe rewalk, like physical medicine and rehab physicians, neurologists, and stroke specialists, are the exact same people who would prescribe this device, so lifeward doesn't need to build a new sales channel from scratch. same reps, same relationships, new product to sell into them.

The deal brought over the Skelable engineering team, with more than 60 years of combined experience across electrical, software, mechanical, and industrial design, so this isn't just buying a patent and a prototype sitting in a drawer, it's buying the people who know how to actually finish building it.

Timeline and risk: on the Q4 2025 earnings call, management reaffirmed the device is expected to be ready for commercial launch in roughly 18 to 24 months, pending further development and regulatory clearance. The regulatory pathway is expected to be 510(k) exempt, which if it holds is a faster and cheaper road to market than a full FDA clearance process. worth noting nothing is guaranteed here, timelines can slip, and 510(k) exempt status isn't locked in until FDA actually treats it that way.

Skelable isn't revenue yet, it's optionality. a cheap, capital efficient bet that turns lifeward from a lower body mobility company into a whole body neuro rehab company, with a built in sales channel and a multi million person addressable market.

nfa dyor (ai assisted post)

Next one in the series, breaking down AlterG for anyone in $LFWD who wants the plain version.

AlterG is an antigravity treadmill. Sounds like sci-fi, but the underlying idea is incredibly practical. You zip into a pair of specialized shorts that lock into an air filled chamber surrounding the lower half of your body. The machine pumps air into that chamber to uniformly lift you, taking pressure off your lower extremities. It can reduce gravitational load down to 20 percent of your total body weight in precise 1 percent increments, letting a physical therapist dial in exactly how much support a patient needs.

Where it came from is a great detail: the underlying tech, called Differential Air Pressure, was originally developed for NASA to help astronauts maintain bone density and muscle mass in zero gravity environments. It was reverse engineered for terrestrial clinical use, which is a fantastic backstory.

Currently, it is used in over 6000 facilities worldwide. You will find them anywhere from elite pro sports training rooms used heavily in the Premier League, NBA, and NFL to local physical therapy clinics treating everyday patients. Elite athletes use it to rehab injuries faster or pack on training volume without joint impact, while patients managing neurological or orthopedic conditions use it for safe, fall risk free gait training.

When you compare it to alternatives like hydrotherapy pools or overhead harness systems, AlterG stands out because the unweighting is completely uniform. It does not distort a person's natural mechanics, which is vital in rehab because the goal is to relearn normal movement patterns, not modified ones. Plus, it skips the massive footprint, plumbing overhead, and high maintenance costs of physical therapy pools.

The mid to high tier systems also come with real time gait analytics tracking symmetry, cadence, and step length and live video monitoring built in. Therapists can see exactly what is happening with a stride on a 21 inch screen and make objective adjustments on the fly.

From a business standpoint, Lifeward has tiered the current lineup nicely to capture the entire market:

NEO: The entry point. Launched to bring core AlterG DAP technology down to a price point smaller, budget conscious clinics can actually afford. You get the same fundamental unweighting tech, just without the higher end monitoring extras.

NEO+: The mid tier and probably the sweet spot for most clinics. Adds live video monitoring and real time gait analytics, tracking symmetry, cadence, and step length, on top of the core NEO platform. This is the tier that gives therapists the data and visual feedback loop to make objective adjustments mid session.

PRO: The top of the line, built for extreme speeds and elite performance training. This is what you see in pro sports training rooms and Olympic level facilities. Built to handle serious training volume and higher speeds.

AlterG is not a niche gadget, it is an established, widely adopted recovery standard with NASA pedigree, real clinical backing, and a tiered commercial strategy built to protect its position as the category leader.

Not financial advice. Just tracking the tech.

Quick rundown for anyone holding $LFWD who doesn't have a medical background and wants to actually understand what they own.

ReWalk is a wearable robotic exoskeleton. think a set of motorized braces that go over the hips and knees, strapped onto someone who has a spinal cord injury and can't walk on their own. the person leans forward slightly, the device reads that shift in weight, and the motors move the legs in a walking motion. crutches are used for balance. that's it in plain terms, no medical jargon needed.

who it's for: people with spinal cord injuries, ranging from mid back down to lower back level injuries, who would otherwise be in a wheelchair full time.

what makes it stand out from other devices in this space (The Moat): it's the only personal exoskeleton that lets users walk over stairs and curbs, which opens up real world environments instead of just flat indoor surfaces. most competitors are limited to flat ground or clinic settings only. This is Lifeward's primary product moat: ReWalk is the only personal exoskeleton to receive FDA clearance for use on stairs and curbs in the United States. The FDA even granted it a "Breakthrough Device" designation because of this. No other company has this clearance, meaning ReWalk holds a functional monopoly on navigating real-world architectural barriers like a flight of steps or a sidewalk curb. ReWalk is built and cleared for actual day to day use at home and in the community, not just rehab sessions.

the newest version, ReWalk 7, added a new crutch control system that makes it easier and faster to learn how to use, which matters a lot since training time has historically been a barrier for these devices.

benefits aren't just "they can walk again." studies tied to ReWalk use point to improvements in spasticity, trunk control, bladder and bowel function, and mental health, on top of the obvious mobility gain. that's a big deal for a population that deals with a lot of secondary health issues from being seated all day every day.

coverage is the other piece that matters for the business side (The Reimbursement Moat): Because these devices cost upwards of $100k, insurance coverage is the business model, and Lifeward has established a massive first-mover moat here. Medicare added ReWalk to its brace benefit category back in January 2024, creating a standardized, national payment pathway. Following that landmark ruling, commercial payers are falling into line. More recently three of the largest Medicare Advantage insurers, Aetna, Humana, and UnitedHealthcare, have all approved coverage for qualifying patients, representing close to 16 million covered lives between them. This commercial backing forms a massive barrier to entry for competitors. wider insurance coverage means more patients can actually access the device without paying out of pocket, which is the real unlock for sales growth.

ReWalk isn't just a cool robot, it's a clinically proven mobility device with real health benefits, expanding insurance backing, and a feature set (stairs/curbs, easier training) that puts it ahead of where the competition currently sits.

​

Quick background for anyone new here. LFWD, formerly known as ReWalk Robotics, makes a wearable robotic exoskeleton that lets people with spinal cord injuries stand up and walk. Incredible tech, but for years the company had a huge problem. The device works, but almost nobody could actually get insurance to pay for it. That is finally changing, and it is the biggest reason people are paying attention to this stock right now.

Let me break down how insurance reimbursement actually works here, in plain language.

Step 1: Getting a code

Before any insurance company can pay for a medical device, that device needs its own billing code. Think of it like a barcode that tells Medicare and private insurers exactly what they are being asked to pay for. Without a code, insurers just say no because they have no system to process the claim.

In 2020, ReWalk got its first ever code for an exoskeleton, called HCPCS code K1007. This was a big deal because no exoskeleton had ever gotten one before. It opened the door, but it did not set a price yet.

Step 2: Getting a category

Next the government has to decide what kind of medical equipment this even is. In 2023 Medicare officially put personal exoskeletons into the brace benefit category. This matters because braces get paid out in one lump sum instead of small recurring payments, which is a much cleaner and more predictable path to revenue for the company.

Step 3: Getting a price

Having a code and a category means nothing without an actual dollar amount attached. This is where things really turned. In April 2024, Medicare finalized a payment rate for K1007 at exactly $91,031.93 per device. That is a real number the government has agreed to pay, not a hope or a projection.

Step 4: Getting private insurers on board

Medicare is only part of the picture. Private insurance companies make their own decisions independently, and this used to be the biggest wall for the company. Cigna became the first major private insurer to move away from a blanket denial policy back in 2019, agreeing to review cases individually instead of rejecting them outright.

That trickle turned into real momentum recently. Over the winter, three of the biggest Medicare Advantage insurers in the country, UnitedHealthcare, Humana, and most recently Aetna, all independently approved coverage for individual patients. Together those three companies cover about 16 million people. When three separate giant insurers reach the same conclusion on their own, it tells you the clinical evidence is doing its job.

The Management Shift: From Product Pioneers to Commercial Execution

This brings us to the real catalyst behind why this plumbing is finally working. For years, the old management team operated purely like a tech pioneer. They did the heavy lifting of keeping the company alive, getting FDA clearances, and pushing for that initial raw billing code. But they were engineers and product people, not commercial operators. They built an incredible machine, but they did not know how to systematically force insurers to open their checkbooks.

The turning point came when the company transitioned leadership to Mark Grant. The major advantage of the new management team is that they are execution focused executives who actually understand how to weaponize the regulatory infrastructure the old team left behind.

Instead of treating the Medicare codes like a nice press release, new management built a dedicated internal reimbursement team. They stopped just waiting for inbound interest and started systematically pushing individual claims through the pipeline, forcing insurers to honor the federal fee schedule. You can see it directly in the data: the sudden cascade of wins with UnitedHealthcare, Humana, and Aetna did not happen by accident. It happened because the new leadership knows exactly how to work the gears of the insurance system, turning legal and administrative precedents into predictable corporate revenue.

Why this actually matters for the turnaround

Before all this, Lifeward was basically selling a life changing device that almost nobody could afford out of pocket. Now there is an actual paved road from a doctor's prescription to an insurance check. Every new code, category, price, and insurer approval removes one more obstacle between the product and the patient who needs it. That is not just good PR, that is the exact plumbing a medical device company needs in place before it can scale revenue.

There was even an administrative law judge ruling this year in favor of a Medicare patient's appeal, confirming the ReWalk is a reasonable and necessary device. Rulings like that build precedent and make future approvals much harder for insurance companies to fight.

This is the boring unsexy part of the story that does not show up in a hype headline, but it is genuinely the foundation the whole bull case is being built on.

Mark Grant took over as President and CEO in June 2025, replacing Larry Jasinski who had run the company (then still ReWalk Robotics) for years. Jasinski stuck around as Co-CEO briefly and then in an advisory role through the end of 2025 to help with the handoff, ensuring a planned transition rather than a chaotic exit.

His resume is worth walking through because it explains a lot of what's happened since he arrived. Grant spent almost two decades at Medtronic (2004 to 2023), working his way up to Vice President for the Americas within the Diabetes Group. In that seat, he had full P&L responsibility for a business doing north of $1.5 billion a year. His mandate there covered building out sales channels, securing critical access to new payer relationships (including the VA), managing complex revenue cycle operations, and restructuring the business as market conditions shifted.

Before Medtronic, he was at Bristol Myers Squibb and FLA Orthopedics in commercial leadership. Right before joining Lifeward, he was President of Americas and Chief Commercial Officer at IMRA Surgical, where he built out the go-to-market infrastructure for a brand-new category of soft-tissue robotic surgical procedures. He holds a BS in industrial technology from East Carolina University. The clear through-line across his 30-year career is commercial buildout, reimbursement navigation, and channel development in medtech—he's an operational sales guy, not a bench scientist.

That background is exactly why the board brought him in with a clear mandate: get Lifeward to profitability. On the ReWalk side specifically, his first year has been about capitalizing on structural tailwinds already in motion: the newly established Medicare reimbursement pathway for personal exoskeletons, the launch of the ReWalk 7, and the transition to in-house manufacturing to lift margins. We started seeing that discipline show up clearly in the Q2 2025 numbers, which posted a gross margin near 44% and cut quarterly cash burn to under $4 million.

A side story that might turn out to be a major catalyst is Grant’s deep diabetes commercial experience, this explains why Lifeward executed the strategic transaction with the Oramed oral insulin platform in January 2026. While it’s a real piece of the corporate structure now, the core day-to-day value driver remains the exoskeleton and rehab portfolio.

Turning around a small-cap medtech company isn't an engineering problem anymore; it's a commercial execution and insurance reimbursement problem. That is the exact game Grant has played and won at scale. Running a $1.5B P&L means dealing with payers, distributors, and revenue cycle headaches vastly more complex than what LFWD faces. With the Medicare reimbursement framework finally active, if he can replicate even a fraction of his Medtronic channel expansion here, the stock is completely mispriced for that outcome.

Quick context if you are new to LFWD. Lifeward, which used to be called ReWalk Robotics, builds actual physical medical tech that helps people move again after spinal cord injuries or strokes. This is not some hype story about a concept. It is real hardware being used right now in clinics and homes.

If you want a quick feel for what they actually build, take a break from squinting at SEC filings and just watch the gear in action.

The ReWalk 7 Exoskeleton

This is a personal wearable bionic suit for people with lower limb paralysis. It lets users stand, walk, turn, and even handle stairs.

The best part is that this is not just a cool video from a tech convention. With Medicare coverage expanding in the US, this is actively being prescribed and paid for by insurance.

Watch it handle stairs: https://www.youtube.com/watch?v=gWEDF6Mx5WA

The AlterG Anti Gravity Treadmill

This one uses air pressure technology derived from NASA to literally unweight a patient by up to 80 percent.

It looks a little funny, almost like you are zipped into a giant bubble wrap suit, but it is a massive commercial hit. Thousands of clinics and pro sports teams use it so athletes can run without wrecking their joints during rehab.

Watch it defy gravity: https://www.youtube.com/watch?v=Qllqv8S\_6QU

Seeing these two in motion makes the whole thesis click way faster than a massive financial model. You have a company solving real human mobility challenges with two completely distinct products that already have strong clinical adoption.

Definitely worth five minutes of your time if you are building a position or just watching from the sidelines.

Alpha Tau has hit most of their stated H1 milestones, which sets up a fairly loaded back half of the year. I put together a straightforward breakdown of where they stand and what's coming.

*Note on process: AI tools were used for research assistance, fact checking, and image generation.

Quick recap. They submitted their first FDA PMA module for skin cancer in January, completed enrollment in the ReSTART pivotal trial in May with 88 patients, and reported early glioblastoma data showing 100% local control and a 67% complete response rate in the first three patients. They presented pancreatic survival data at ASCO in June, and announced a partnership with Tolmar that brought in 35 million in upfront cash and manufacturing support for a prostate cancer program.

That's the foundation. Here is what's actually coming.

Summer 2026

Podium presentation at the AHNS head and neck conference covering their Keytruda combination study. This one hasn't gotten much attention yet.

Full enrollment completion for the IMPACT pancreatic trial, recently expanded to 40 patients with a combination chemotherapy arm added.

The final 7 slots in the REGAIN glioblastoma trial filling in, following FDA clearance earlier this month to resume enrollment and add new US sites.

Ongoing commercial activity in Japan where they already hold marketing approval for head and neck cancer.

Late 2026

Top line data from the 88 patient ReSTART pivotal trial in skin cancer. They have Breakthrough Device Designation for this indication, so clean data feeds directly into the remaining PMA modules and puts an early 2027 approval decision in play.

Initial 10 patient data readout from the REGAIN glioblastoma trial. This determines whether the program advances into a US pivotal study.

Early data from the expanded IMPACT pancreatic cohort.

Enrollment and interim data building from the ACAPELLA study in Europe.

2027 and Beyond

Potential FDA approval for recurrent cutaneous squamous cell carcinoma and the start of US commercialization.

Pivotal trial decisions for glioblastoma and pancreatic cancer based on the late 2026 readouts.

First patient treatments under the Tolmar prostate program.

A few things worth noting. The ReSTART readout is the most important near-term event from a regulatory standpoint. It's not speculative, it's the direct input into the PMA submission. The glioblastoma data is the higher-variance event. Brain cancer is a historically difficult indication and no one is pricing in much from that program right now, which is probably the right call until the 10 patient data is actually in hand. If it holds up, that changes the conversation pretty quickly.

The Tolmar deal is underappreciated as a structural piece here. It doesn't just add cash, it adds a credible commercial partner with existing infrastructure in the oncology space.

NFA DYOR.

We got confirmation from CFO Raphi Levy yesterday that Alpha Tau will be dropping survival data from their pancreatic cancer trials at ASCO this weekend.

The median survival for patients who failed first line Folfirinox is 10.1 months. In an early combined Alpha DaRT + Folfirinox trial, 8 out of 10 patients were still alive at 15 months (as of January 2025). Small sample size, early data but this direction and results will be very hard to ignore.

Presenting safety, efficacy AND survival data at ASCO, the most prestigious oncology conference in the world, is a BIG deal. 

ASCO takes place this weekend